Novartis Culls 10% of Pipeline, Doubles Down on Five Core Therapeutic Areas

To sharpen its focus on its core therapeutic areas, Novartis is discontinuing or licensing out 10% of its clinical development programs, the company announced Tuesday during its first-quarter financial report call with investors.